Testing GT801 cell therapy for blood cancer and AIHA
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tests an investigational cell therapy called GT801 for people whose CD19-positive blood cancer (B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) has not responded to standard treatments. The therapy is made from your own immune cells, modified to target and destroy cancer cells or abnormal immune cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a CD19-positive B-cell blood cancer (like B-ALL, CLL, or B-NHL) or autoimmune hemolytic anemia (AIHA) that has come back or not responded to at least two prior treatments.
- Your cancer cells must test positive for CD19 (a protein marker) – not needed if you have AIHA.
- You must be generally well enough to carry out daily activities (ECOG score 0 or 1) – not needed if you have AIHA.
- You have not had a stroke, severe heart problems, or uncontrolled high blood pressure or diabetes in the last 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new cell therapy called GT719 for people with B-cell leukemia or lymphoma that has not responded to standard treatments. The therapy targets a protein called CD19 on cancer cells, aiming to kill them.
This early-stage study tests a new cell-based treatment called GT801 for autoimmune diseases that haven't responded well to standard medicines. It aims to see if this approach is safe and helps reduce symptoms in conditions like lupus, vasculitis, and scleroderma.
This trial tests a new treatment called GT801, a type of CAR-T cell therapy, for people with moderate to severe autoimmune diseases that have not responded to standard treatments. It aims to see if GT801 can safely and effectively control the disease.
This trial tests an experimental cell therapy using your own immune cells (gamma-delta T cells) that are engineered to find and kill cancer cells that carry a protein called CD19. It is for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments.
This trial tests a new type of immune cell therapy (called iNKT cells) that is designed to find and attack leukemia cells. It's for people whose leukemia has come back or hasn't gone away after standard treatments. The goal is to see if this therapy is safe and can help.
This trial tests a new treatment called GI001 for people with B-cell lymphoma or B-cell leukemia that has come back or hasn't responded to previous treatments. It aims to see if GI001 can help when other options have failed, and it may be an option if you haven't had CAR-T therapy before.
Hear when a new Autoimmune Hemolytic Anemia (AIHA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.